Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
About this study
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.
- Condition
- Myeloid Leukemia, Acute
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 3
- Minimum age: 18 years
- Study condition: Myeloid Leukemia, Acute
- FLT3 mutated
Exclusion 1
- Respoder to therapy
Where
1 site, 1 recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
Bologna, Italy
Contact
-
Emanuela Ottaviani, MD
0039 0512144055 emanuela.ottaviani@aosp.bo.it
Potential match only. Final eligibility is determined by the study team.